Literature DB >> 3109638

Clinical evaluation of lysuride in the management of hyperprolactinaemia.

P M Bouloux, G M Besser, A Grossman, P J Moult.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3109638      PMCID： PMC1246488          DOI： 10.1136/bmj.294.6583.1323-a

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  4 in total

1.  Rapid regression of macroprolactinomas by the new dopamine partial agonist terguride.

Authors:  K J Gräf; D Köhler; R Horowski; R Dorow
Journal:  Acta Endocrinol (Copenh)       Date:  1986-04

2.  Intolerance of bromocriptine: is metergoline a satisfactory alternative?

Authors:  I F Casson; B A Walker; L J Hipkin; P E Belchetz
Journal:  Br Med J (Clin Res Ed)       Date:  1985-06-15

3.  Size reduction of macroprolactinomas by bromocriptine or lisuride treatment.

Authors:  P Chiodini; A Liuzzi; R Cozzi; G Verde; G Oppizzi; D Dallabonzana; B Spelta; F Silvestrini; G Borghi; G Luccarelli; E Rainer; R Horowski
Journal:  J Clin Endocrinol Metab       Date:  1981-10       Impact factor: 5.958

4.  Comparison of the clinical activity of mesulergine and pergolide in the treatment of hyperprolactinaemia.

Authors:  A Grossman; P M Bouloux; R Loneragan; L H Rees; J A Wass; G M Besser
Journal:  Clin Endocrinol (Oxf)       Date:  1985-05       Impact factor: 3.478
  4 in total
  1 in total

Review 1.  A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation.

Authors:  J Webster
Journal:  Drug Saf       Date:  1996-04       Impact factor: 5.606
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.